source
- Experts say Grail’s multi-cancer blood test not yet ready for routine screeningAt the ASCO 2026 meeting in Chicago, Grail presented its multi-cancer early detection blood test, which the company markets as a tool to identify several cancers at an early stage. Independent exp…
- Endpoints Weekly previews ASCO coverage, discusses AI in research and shifting immunotherapy strategiesThe weekly newsletter returns with a team of reporters stationed in Chicago for the upcoming ASCO meeting. It promises on‑the‑ground insights from the conference. One focus will be the role of art…